Advertisement

Perspectives in Radiomics for Personalized Medicine and Theranostics

  • Seunggyun HaEmail author
Perspective
  • 23 Downloads

Abstract

Radiomics handles imaging biomarker from high-throughput feature extraction through complex pattern recognition that is difficult for human to process. Recent medical paradigms are rapidly changing to personalized medicine, including molecular targeted therapy, immunotherapy, and theranostics, and the importance of biomarkers for these is growing day by day. Even though biopsy continues to gold standard for tumor assessment in personalized medicine, imaging is expected to complement biopsy because it allows whole tumor evaluation, whole body evaluation, and non-invasive and repetitive evaluation. Radiomics is known as a useful method to get imaging biomarkers related to intratumor heterogeneity in molecular targeted therapy as well as one-size-fits-all therapy. It is also expected to be useful in new paradigms such as immunotherapy and somatostatin receptor (SSTR) or prostate-specific membrane antigen (PSMA)-targeted theranostics. Radiomics research should move to multimodality (CT, MR, PET, etc.), multicenter, and prospective studies from current single modality, single institution, and retrospective studies. Image-quality harmonization, intertumor heterogeneity, and integrative analysis of information from different scales are thought to be important keywords in future radiomics research. It is clear that radiomics will play an important role in personalized medicine.

Keywords

Radiomics Personalized medicine Theranostics Oncology PET 

Notes

Compliance with Ethical Standards

Conflict of Interest

Seunggyun Ha declared that this work was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea (NRF) (no. 2018R1D1A1A02086383).

Ethical Approval

This work does not contain any studies with human participants or animals performed by any of the authors. For this type of study formal consent is not required.

Informed Consent

None.

References

  1. 1.
    Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout RG, Granton P, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441–6.CrossRefGoogle Scholar
  2. 2.
    Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278:563–77.CrossRefGoogle Scholar
  3. 3.
    Yip SS, Aerts HJ. Applications and limitations of radiomics. Phys Med Biol. 2016;61:R150.CrossRefGoogle Scholar
  4. 4.
    Sala E, Mema E, Himoto Y, Veeraraghavan H, Brenton J, Snyder A, et al. Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol. 2017;72:3–10.CrossRefGoogle Scholar
  5. 5.
    Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability — an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220.CrossRefGoogle Scholar
  6. 6.
    Gerlinger M, Swanton C. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine. Br J Cancer. 2010;103:1139.CrossRefGoogle Scholar
  7. 7.
    Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883–92.CrossRefGoogle Scholar
  8. 8.
    Collins DC, Sundar R, Lim JS, Yap TA. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends Pharmacol Sci. 2017;38:25–40.CrossRefGoogle Scholar
  9. 9.
    O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A. Imaging intratumor heterogeneity: role in therapy response, resistance, and clinical outcome. Clin Cancer Res. 2015;21:249–57.CrossRefGoogle Scholar
  10. 10.
    Hatt M, Tixier F, Visvikis D, Le Rest CC. Radiomics in PET/CT: more than meets the eye? J Nucl Med. 2017;58:365–6.CrossRefGoogle Scholar
  11. 11.
    Kalia M. Personalized oncology: recent advances and future challenges. Metabolism. 2013;62:S11–S4.CrossRefGoogle Scholar
  12. 12.
    Mok TS, Wu Y-L, Thongprasert S, Yang C-H, Chu D-T, Saijo N, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947–57.CrossRefGoogle Scholar
  13. 13.
    Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.CrossRefGoogle Scholar
  14. 14.
    Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai C-M, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013;105:595–605.CrossRefGoogle Scholar
  15. 15.
    Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.CrossRefGoogle Scholar
  16. 16.
    Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54.CrossRefGoogle Scholar
  17. 17.
    Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500–1.CrossRefGoogle Scholar
  18. 18.
    Ahn B-C. Personalized medicine based on theranostic radioiodine molecular imaging for differentiated thyroid cancer. Biomed Res Int. 2016;2016:1680464.Google Scholar
  19. 19.
    Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.CrossRefGoogle Scholar
  20. 20.
    Lütje S, Heskamp S, Cornelissen AS, Poeppel TD, van den Broek SA, Rosenbaum-Krumme S, et al. PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status. Theranostics. 2015;5:1388.CrossRefGoogle Scholar
  21. 21.
    Yip SS, Kim J, Coroller TP, Parmar C, Velazquez ER, Huynh E, et al. Associations between somatic mutations and metabolic imaging phenotypes in non-small cell lung cancer. J Nucl Med. 2017;58:569.CrossRefGoogle Scholar
  22. 22.
    Bang J-I, Ha S, Kang S-B, Lee K-W, Lee H-S, Kim J-S, et al. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [18F] FDG PET/CT scans in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging. 2016;43:422–31.CrossRefGoogle Scholar
  23. 23.
    Ha S, Park S, Bang J-I, Kim E-K, Lee H-Y. Metabolic radiomics for pretreatment 18F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis. Sci Rep. 2017;7:1556.CrossRefGoogle Scholar
  24. 24.
    Park S, Ha S, Lee S-H, Paeng JC, Keam B, Kim TM, et al. Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor. PLoS One. 2018;13:e0189766.CrossRefGoogle Scholar
  25. 25.
    Cook GJ, O’Brien ME, Siddique M, Chicklore S, Loi HY, Sharma B, et al. Non-small cell lung cancer treated with Erlotinib: heterogeneity of 18F-FDG uptake at PET—association with treatment response and prognosis. Radiology. 2015;276:883–93.CrossRefGoogle Scholar
  26. 26.
    Choi H, Na KJ. Integrative analysis of imaging and transcriptomic data of the immune landscape associated with tumor metabolism in lung adenocarcinoma: clinical and prognostic implications. Theranostics. 2018;8:1956.CrossRefGoogle Scholar
  27. 27.
    Na KJ, Choi H. Tumor metabolic features identified by 18F-FDG PET correlate with gene networks of immune cell microenvironment in head and neck cancer. J Nucl Med. 2018;59:31–7.CrossRefGoogle Scholar
  28. 28.
    Galavis PE, Hollensen C, Jallow N, Paliwal B, Jeraj R. Variability of textural features in FDG PET images due to different acquisition modes and reconstruction parameters. Acta Oncol. 2010;49:1012–6.CrossRefGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2019

Authors and Affiliations

  1. 1.Radiation Medicine Research InstituteSeoul National University College of MedicineSeoulSouth Korea
  2. 2.Department of Nuclear MedicineSeoul National University HospitalSeoulSouth Korea

Personalised recommendations